{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030557","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.305094+00:00","generated_at":"2026-05-30T21:36:46.661715+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharma to acquire Increlex from Ipsen for $22.5M upfront plus $7.5M inventory","bullets":["Acquisition of Increlex (mecasermin injection) for severe primary IGF-1 deficiency; approved in 40 territories.","Total upfront consideration $30M ($22.5M asset purchase + $7.5M inventory) plus $2.5M on each of first two anniversaries.","Credit facility expanded to $30M from SWK Holdings; interest at SOFR+6.75%; 289,736 warrant shares at $5.32.","Ipsen reported 2023 global sales of €17.3M for Increlex; Eton to immediately commercialize in U.S. after closing.","Closing expected near year-end 2024; all-cash transaction subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030557","json":"https://secwatch.observer/filing/0001437749-24-030557.json","markdown":"https://secwatch.observer/filing/0001437749-24-030557.md","text":"https://secwatch.observer/filing/0001437749-24-030557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924030557/0001437749-24-030557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924030557/eton20240930_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:36:46.661715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}